KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) EBIT Margin (2018 - 2025)

Vir Biotechnology (VIR) has disclosed EBIT Margin for 8 consecutive years, with 74.79% as the latest value for Q4 2025.

  • Quarterly EBIT Margin rose 87195.0% to 74.79% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 699.18% through Dec 2025, up 14531.0% year-over-year, with the annual reading at 699.18% for FY2025, 9210.0% up from the prior year.
  • EBIT Margin hit 74.79% in Q4 2025 for Vir Biotechnology, up from 72267.92% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 82.26% in Q1 2022 to a low of 72267.92% in Q3 2025.
  • Historically, EBIT Margin has averaged 6258.75% across 5 years, with a median of 691.23% in 2022.
  • Biggest five-year swings in EBIT Margin: skyrocketed 811025bps in 2022 and later crashed -6254926bps in 2025.
  • Year by year, EBIT Margin stood at 70.35% in 2021, then plummeted by -533bps to 304.6% in 2022, then tumbled by -172bps to 828.12% in 2023, then dropped by -14bps to 946.74% in 2024, then soared by 92bps to 74.79% in 2025.
  • Business Quant data shows EBIT Margin for VIR at 74.79% in Q4 2025, 72267.92% in Q3 2025, and 9754.28% in Q2 2025.